Skip to content
Teethgrinder – Lifestyle
Author:
Oculis Holding AG
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
October 1, 2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors
September 30, 2026
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
August 24, 2026
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
August 10, 2026
Oculis Reports Q2 2026 Financial Results and Provides Company Update
August 6, 2026
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
August 3, 2026
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
July 2, 2026
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
June 11, 2026
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
June 9, 2026
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
June 8, 2026
1
2
Next Page
→